One Percent Rule Checklist For Safer Forex Trading Risk 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
REDWOOD CITY, Calif., April 24, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017. At 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing first quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.
Conference Call Information
When: Monday, May 8, 2017 at 4:30 p.m. EDT
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 8313325
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O’Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
